Miriam Tao

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

Ghee Chong Koo, Soo‐Yong Tan, Tiffany Tang et al. · Cancer Discovery · 2012 · 274 citations · Full text

Life Sciences, Cell Biology, Oncology +15

Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore

Siok‐Bian Ng, Kin Wai Lai, Sivakumar Murugaya et al. · Modern Pathology · 2004 · 192 citations · Full text

Medicine, Oncology, Pathology +16

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab

Lynette Ngo, Siew Wan Hee, L C Lim et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 104 citations

Medicine, Oncology, Cancer Immunology +13

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis

Yu Xuan Koo, Matthew Zirui Tay, Yii Ean Teh et al. · Annals of Hematology · 2011 · 104 citations

Medicine, Oncology, Pharmacology +14

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study

Zheng Li, Yi Xia, Jie-Rong Chen et al. · The Lancet Oncology · 2016 · 96 citations

Life Sciences, Genetics, Oncology +16